Atom Investors’s BridgeBio Pharma BBIO Stock Holding History

Atom Investors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,652	Closed	-$2.65M	–	841
2026 Q1	$2.65M	Buy	+35,652	New	+$2.58M	0.19%	184

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Atom Investors's BBIO Position: Q2 2026 in Review

Atom Investors sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 35,652 shares — an estimated $2.65M sold.

Atom Investors first reported a position in BBIO in Q1 2026 and held it in 1 quarter. The position peaked at $2.65M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Atom Investors reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Atom Investors sold 35,652 BridgeBio Pharma shares in Q2 2026, an estimated $2.65M.
Atom Investors first reported a position in BridgeBio Pharma in Q1 2026 and held it in 1 quarter.
Atom Investors's BridgeBio Pharma position peaked at $2.65M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.